Sugi Predict

Sugi Predict / Compounds / SCHEMBL287634

SCHEMBL287634

SCHEMBL287634

O=C(O)c1nccc2ccsc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.42
▸ ASPH Q12797 1/20 0.42
▸ KDM8 Q8N371 1/20 0.42
▸ MAPT P10636 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ BLM P54132 1/20 0.40
▸ AGER Q15109 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ SPR P35270 1/20 0.39
▸ CYP1A2 P05177 2/20 0.36
▸ GPR35 Q9HC97 1/20 0.36
▸ DAO P14920 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ ADORA2A P29274 2/20 0.35
▸ ADORA1 P30542 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL369046 0.84 BRAF (0.38) MAPTALDH1A1SPRHDAC2ADORA2A
SCHEMBL5951057 0.84 HDAC2 (0.35) ALDH1A1SPRHDAC2ADORA2AADORA1
SCHEMBL29494911 0.84 BRAF (0.38) MAPTALDH1A1SPRHDAC2ADORA2A
SCHEMBL30605635 0.80 ADORA2A (0.43) KDM4EALDH1A1ADORA2ASMN1; SMN2
SCHEMBL370324 0.80 L3MBTL1 (0.43) KDM4EALDH1A1NPSR1L3MBTL1CYP1A2
SCHEMBL15391120 0.72 HSP90AA1 (0.36) MAPTALDH1A1TSHRSPRHDAC2
SCHEMBL1631599 0.70 KDM4E (0.42) KDM4EASPHKDM8MAPTALDH1A1
SCHEMBL23858526 0.70 KDM4E (0.43) KDM4EASPHKDM8MAPTALDH1A1
SCHEMBL2881001 0.70 ADORA2A (0.57) ADORA2AADORA1CDK9DYRK1A
SCHEMBL369929 0.70 DAO (0.39) KDM4EASPHKDM8MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2511268-B1 OXAZINE DERIVATIVE SHIONOGI & CO (JP) 2016-07-13 — — EP claimed
CN-102482268-B 2-Aminodihydro [1,3] thiazines as BACE2 inhibitors for the treatment of diabetes HOFFMANN LA ROCHE 2014-11-26 — — CN claimed
EP-2509966-B1 AMINO OXAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-10-22 — — EP claimed
US-20140221360-A1 USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES HOFFMANN-LA ROCHE INC. (US) 2014-08-07 — — US claimed
US-20130096107-A1 USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES HOFFMANN-LA ROCHE INC. (US) 2013-04-18 — — US claimed
EP-2509966-A1 AMINO OXAZINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-10-17 — — EP claimed
CN-102652129-A Amino oxazine derivatives HOFFMANN LA ROCHE 2012-08-29 — — CN claimed
EP-2475658-A1 2 -AMINODIHYDRO [1, 3]THIAZINES AS BACE 2 INHIBITORS FOR THE TREATMENT OF DIABETES F. Hoffmann-La Roche AG (CH) 2012-07-18 — — EP claimed
CN-102482268-A 2-Aminodihydro [1,3] thiazines as BACE2 inhibitors for the treatment of diabetes HOFFMANN LA ROCHE 2012-05-30 — — CN claimed
CN-102421760-A Dihydropyrimidinones useful as BACE2 inhibitors HOFFMANN LA ROCHE 2012-04-18 — — CN claimed
US-20110065695-A1 USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES HOFFMANN-LA ROCHE, INC. 2011-03-17 — — US claimed
WO-2010128058-A1 DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 — — WO claimed
US-20100286158-A1 DIHYDROPYRIMIDINONES HOFFMANN-LA ROCHE, INC. 2010-11-11 — — US claimed
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INT (DE) 2026-03-19 — — US disclosed
US-11697636-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2023-07-11 — — US disclosed
EP-3187490-B1 SUBSTITUTED BENZAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2022-04-06 — — EP disclosed
CN-1886391-A Teramic acid and threonine as beta-secretase inhibitors HOFFMANN LA ROCHE (CH) 2006-12-27 — — CN disclosed
EP-1689729-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. Hoffmann-La Roche AG (CH) 2006-08-16 — — EP disclosed
WO-2005058857-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 — — WO disclosed
US-20050119329-A1 Tetronic and tetramic acids HOFFMANN-LA ROCHE INC. 2005-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096107-A1 USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES SLC5A2, SLC5A1, GLP1R KDM4E 1845/4885ASPH 441/4885KDM8 1663/4885
US-20140221360-A1 USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES SLC5A2, SLC5A1, GLP1R KDM4E 1845/4885ASPH 441/4885KDM8 1663/4885
US-20110065695-A1 USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES SLC5A2, SLC5A1, GLP1R KDM4E 1845/4885ASPH 441/4885KDM8 1663/4885
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, CD22, CD79B KDM4E 3096/4885ASPH 1793/4885KDM8 1495/4885
US-20050119329-A1 Tetronic and tetramic acids BACE1, PSEN1, BACE2 KDM4E 3412/4885ASPH 441/4885KDM8 1647/4885
US-11697636-B2 Substituted benzamides TAAR1, TAAR5, NPY1R KDM4E 1864/4885ASPH 744/4885KDM8 1922/4885
US-20100286158-A1 DIHYDROPYRIMIDINONES BACE2, BACE1, PSEN2 KDM4E 2548/4885ASPH 380/4885KDM8 1364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.